SYDNEY, Aug. 13, 2018 /PRNewswire-PRWeb/ -- The announcement was made by Hon. Greg Hunt MP Minister
The funds, to be spread over three years, will enable AADPA, the leading professional body for ADHD in Australia, to help formalize agreed best practices for the diagnosis and treatment of ADHD nationally, and to identify key research and public policy priorities.
ADHD is the most prevalent mental health disorder of childhood worldwide and persists into adulthood in around 60% of individuals.
"ADHD is immensely important" says Greg Hunt, MP. "Up to 7% of Australian children have ADHD. It can affect their families, their communities, but most importantly, it can affect their learning capabilities and their own relations, their own sense of mental health. It can also lead to issues throughout life. This funding is provided to AADPA to assist their work, their research, and the ability to provide better treatment."
According to Professor Mark Bellgrove, AADPA President, "There is a real need at present for high quality data on ADHD in Australia including its inter-relationships with other mental health problems, and its impact on society."
"Moreover, there are differences in diagnosis and treatment practices across Australia. A unified approach is urgently needed. This funding will provide clear guidance for all health professionals and Australian families dealing with ADHD."
Professor David Coghill, AADPA Board member said: "ADHD is a lifelong condition affecting 1.2 million Australians. For too long its diagnosis has been marred by negative attention that has failed to recognise the very serious lifetime outcomes for children, adolescents and adults living with ADHD. Early diagnosis and good treatment improve individual outcomes significantly and reduce the social and financial burden on society."
FACTS ABOUT ADHD
SOURCE Australian ADHD Professionals Association
Subscribe to our Free Newsletters!
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...
Are you gluten intolerant? Stay away from gluten allergy and celiac disease by shifting to ...
Moxetumomab pasudotox-tdfk is used to treat hairy cell leukemia (a form of chronic lymphocytic ...View All